Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide Combination Maintenance Therapy for Frontline Multiple Myeloma Patients

NCT03733691 is registered in ClinicalTrials.gov with Oncotherapeutics as lead sponsor.

NCT NCT03733691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03733691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide Combination Maintenance Therapy for Frontline Multiple Myeloma Patients
Lead sponsor
Oncotherapeutics
Phase
Phase 2
Overall status
Terminated
Start date
March 1, 2019
Completion date
October 19, 2023
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed multiple myeloma